Poly-ADP ribose polymerase inhibitors (PARPi) have demonstrated activity in both adjuvant and metastatic settings in germline BRCA1 and BRCA2 Pathogenic Variant carriers and the diagnosis of metaplastic breast cancer should certainly not dissuade clinicians from ordering germline testing if other local criteria are met [2]. This evidence concerns the gene BRCA1 and breast carcinoma.